Introduction
The dihydroquinoxalin-2-ones are bicyclic, benzene-fused ketopiperazines with the carbonyl group in position 2.
1,2 They are of broad interest due to their potential therapeutic properties, particularly antiviral and anti-inflammatory activities, as demonstrated in several studies. [3] [4] [5] Furthermore, this heterocyclic scaffold is particularly chemically versatile since A summary of recent synthetic approaches to 3,4-dihydroquinoxalin-2-ones is discussed herein along with highlights of biological activity. The synthetic approaches include access to enantiopure 3,4-dihydroquinoxalin-2-ones from chiral pool amino acids via coupling/cyclization, Michael addition/cyclization cascades, 3,3-disubstituted systems from multicomponent couplings, Bargellini reaction, or photochemical reduction.
De Brabander et al. have reported the synthesis of 3-substituted dihydroquinoxalin-2-ones via a mild Ullmann-type, ligand-free amination of enantiopure α-amino acids with N-Boc-2-iodoanilines followed by cyclization. 6 The coupling reaction worked well with moderate to good yields (51-90%) with the exception where the amino acid contains the strongly electron-withdrawing p-trifluoromethylphenyl group. Both methyl-and cyano-substituted iodoaniline, as well as unsubstituted iodoaniline were tolerated. Upon treatment with TFA, the coupling products were converted into substituted dihydroquinoxalin-2-ones in good yields (79-90%) for all substrates. Both the coupling reaction and the cyclization occurred without racemization, and the dihydroquinoxalin-2-ones were isolated in excellent enantiomeric excess (>98% ee). Park and coworkers recently demonstrated an asymmetric formation of substituted quinoxalin-2-ones through a chiral auxilliary approach. 7, 8 A stereoselective substitution of Enantiopure dihydroquinoxalin-2-ones enantiopure α-bromophenylacetates with o-phenyldiamines was demonstrated, employing α-bromophenylacetates enantioenriched through crystallization-induced dynamic resolution. The reaction yielded quinoxalin-2-ones in good to excellent yields (79-95%) and in excellent enantiomeric excess (99:1 er).
Michael addition strategies
A simple method for the synthesis of 3-nitromethylsubstituted quinoxalin-2-ones was recently reported. 9 The reaction involves a Michael addition/cyclization cascade process in which both symmetrical and unsymmetrical o-phenylenediamines are used to obtain 3-nitromethylsubstituted quinoxalin-2-ones in moderate to good yields (51-81%). Reactions with unsymmetrical o-phenylenediamines afforded regioisomeric mixtures without notable selectivity. Upon refluxing in aqueous solution, the nitromethyl group eliminates, yielding the corresponding quinoxalin-2(1H)-ones. Rozhkov and coworkers demonstrated a different Michael addition approach, in which the reaction of o-phenylenediamine with maleic acid derivatives afforded 3-substituted 3,4-dihydroquinoxalin-2-ones in moderate to good yields (55-72%). 10 The reaction also works with diethyl maleate and cyclic anhydrides. By employing the Michael addition strategy starting with pyrrole-2,5-diones, they were able to achieve generally higher yields (72-80%) of the desired heterocycle.
3,3-Disubstituted quinoxalin-2-ones
Hu and coworkers presented an effective Rh(II)-catalyzed threecomponent coupling method for producing α-arylserine derivatives by trapping carbene-derived ammonium ylides with formaldehyde. 11 Further it was demonstrated that the α-serine product upon Boc-protection and subsequent Pd-catalyzed hydrogenolysis gives 3,3-disubstituted quinoxalin-2-one in overall 54% yield for the sequences. Although only one example was presented, the method is of potential interest for the synthesis of 3,3-disubstituted systems. Recently Stokes and coworkers demonstrated the formation of 3,3-disubstituted dihydroquinoxalin-2-ones using the Bargellini reaction of o-phenylenediamines and substituted trichloromethylcarbinol electrophiles under phase-transfer conditions. 12 The reaction works with differently substituted trichloromethylcarbinols resulting in racemic products and can be extended to heteroatom-containing substrates as well as spirocyclic systems. The best yields were observed with trichloromethylcarbinol bearing methyl groups. A variety of electronically diverse phenylenediamines could be employed in moderate to excellent yields (33-93%). For unsymmetrical diamines, the regioselectivity was generally low, but up to 4.7 : 1 ratio could be achieved with electronwithdrawing substituents. Notably, the regioselectivity switched when going from electron-donating to electronwithdrawing substituents.
Spirocyclic quinoxalin-2-ones
Zou and coworkers reported a clever approach for the synthesis of spirocyclic 3,4-dihydroquinoxalin-2-ones in moderate to excellent yields (31-95%) under mild conditions through a condensation of α-chlorooxoindoles with o-phenylenediamines. 13 The reaction proceeds by initial ring opening of the oxoindole by the diamine, followed by double cyclization to generate the spirocyclic system. A variety of substitution patterns were tolerated both on the oxoindole and the phenylenediamine substrates. Kutateladze and coworkers reported an exotic photoassisted intramolecular cycloaddition offering an alternative route to access spirocyclic quinoxalin-2-one scaffold incorporated into molecules with highly complex ring systems.
Spirocyclic quinoxalin-2-ones (continued)
Utilizing the photoactive core of quinoxalonone and a pyrrole-containing unsaturated pendant based on L-phenylalanine, they demonstrated a stereoselective (4+2) cycloaddition resulting in enantiopure product (>40% yield). This represents an innovative synthetic approach to substituted enantiopure 3,4-dihydroquinoxalin-2-one systems starting directly from the fully oxidized quinoxalin-2(1H)-one system.
Highlights of biological activity
Several studies have established biological activities for 3,4-dihydroquinoxalin-2-ones.
3-5,15,16 3,4-Dihydroquinoxalin-2-one GW420867X (entry 1) has undergone clinical trials started in 2001. It was administered to HIV-1 infected patients, both alone and in combination with already approved antiHIV-1 drugs. The compound was well tolerated and displayed potent antiviral activity in this study. 17 Patel and coworkers combined features from two potent antiHIV drug candidates to study the SAR of hybrid structures such as 3-cyclopropylethynyl-4-ethoxycarbonyl-3-methyl-3,4-dihydroquinoxalin-2-one (entry 2). The hybrids included structural elements inspired by the drug efavirenz, as well as the quinoxalin-2-one core of GW420867X. Although the compound displayed potency as a non-nucleoside reverse transcriptase inhibitor (NNRTI), it was not further developed due to poor bioavailability in rhesus monkeys. 18 Mahaney and coworkers studied several compounds containing the 3,4-dihydroquinoxalin-2-one core as estrogen receptor ligands. The two main types studied had N-4 arylsulfonyl and benzoyl substituents. Several of the derivatives tested displayed ligand potency, but compounds such as represented in entry 3 yielded the best results. 19 Chen et al. studied dihydroquinoxalin-2-one acetamides containing bicyclic amines as bradykinin B1 receptor antagonists. Previous studies have shown that 3-chloro-4-methyl substitution on the N-phenylsulfonamide was preferred. In this study, they mainly investigated different substituents at the piperidine ring and showed that a switch to more lipophilic groups (e.g., piperidine), instead of more simple amines, caused increased potency, while maintaining a simpler, unsubstituted phenylsulfonamide group (entry 4). 20 
